Skip to main content

Table 2 Baseline and follow-up clinical characteristics of the study cohort

From: The association between variants in PLA2R and HLA-DQA1 and renal outcomes in patients with primary membranous nephropathy in Western China

Characteristic Patients with PMN (n = 186)
Baseline  
 Age at biopsy (years) 49.1 ± 13.4
 Male (n, %) 102 (54.8)
 SCr (μmol/L) 68.9 ± 22.5
 eGFR (ml/min/1.73 m2) 100.8 ± 20.7
 Urea (mmol/L) 5.6 ± 2.2
 Alb (g/L) 28.4 ± 19.1
 UA (μmol/L) 362.0 ± 95.5
 24 h-u-pro (g/d) 4.17 (2.31,7.34)
 SBP (mmHg) 128.4 ± 15.2
 DBP (mmHg) 78.5 ± 11.0
 Hypertension (n, %) 47 (25.3)
Follow-up  
 SCr (μmol/L) 92.4 ± 89.1
 eGFR (ml/min/1.73 m2) 90.6 ± 29.9
 Urea (mmol/L) 6.6 ± 3.2
 Alb (g/L) 36.4 ± 8.5
 UA (μmol/L) 373.3.0 ± 106.6
 24 h-u-pro (g/d) 0.86 (0.15,2.65)
 Follow-up time (month) 18.6 (6.7,45.5)
 Endpoint event (n,%) 41 (22.0)
 Therapy  
  Corticosteroid monotherapy (n,%) 29 (15.6)
  Immunosuppression (n,%) 112 (60.2)
  Non- Immunosuppression (n,%) 45 (24.2)
 Treatment effect  
  Corticosteroid monotherapy  
    CR/PR/non-SR (n,%) 12/6/11 (41.4, 20.7, 37.9)
  Immunosuppression  
    CR/PR/non-SR (n,%) 37/21/54 (33.0, 18.8, 48.2)
  Non- Immunosuppression  
    CR/PR/non-SR (n,%) 14/13/18 (31.1, 28.9, 40.0)
  1. The Endpoint event was defined as a combination of ESRD, a 30% reduction of eGFR from baseline and double times increasing of creatinine